Radnor biotech company gets FDA nod to study

nadezhdaqedyxos.blogspot.com
The approval is the second such study authorizatiomn for the Radnor biotechnology companu within the pastthree months. In May, PolyMedix received regulatory approval in Canadwa to begin human testing of itsantibiotic PMX-30063. The company started enrollingy patients ina phase-I safety trial for the antibiotifc at the end of last week. PolyMedix, whicyh is focused on developing new therapeutic drug products to treart infectious diseases and acute cardiovascular disorderx basedon biomimetics, is attempting to commercialize technologyy licensed from the . Biomimetic s are small molecule drugs which mimic the activityof proteins, but are inexpensive to make and formulatwe into drugs.
Nicholas Landekic , PolyMedi x CEO, said PMX-60056 is in an entirely new classx of drug the companycalls PMX-60056 is designed to reverse the effects of which are used afterf surgery and during cardiothoracic procedures, such as cardiac to prevent blood clots from Existing drugs used to turn off heparimn activity have limitations that include difficulty in adjustiny doses, unpredictable efficacy, post-operative bleeding complications and allergicx reactions. “We are proud to be the firsr and only company to be developing this completely new type of Landekic said.
Exton-based signed a license agreement with the Nationall Cancer Institute for the rightws to a monoclonal antibody for a novel antigen identifierd byNCI researchers. The company plans to develop the antibody as a potentia treatment forprostate cancer. Terms of the deal were not